Vir Biotechnology (VIR +27.6%) jumps to all-time highs after announcing a development and manufacturing collaboration with WuXi Biologics (OTCPK:WXXWY) to advance and produce antibodies for a potential coronavirus treatment.
Under the deal terms, WuXi will be responsible for
cell-line development, process and formulation development and early
production for clinical development.
If the antibodies obtain regulatory approvals,
WuXi would hold commercialization rights in China, while Vir has the
rights in all other markets worldwide.
Vir recently said it identified two monoclonal antibodies that bind the coronavirus causing the current outbreak, SARS-Cov-2.
https://seekingalpha.com/news/3545908-vir-biotech-to-partner-wuxi-on-antibodies-to-treat-coronavirus
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.